Mohammed S, Budamagunta S, Khan W, Khan M, Lippmann S
Cureus. 2024; 16(10):e72778.
PMID: 39618596
PMC: 11608085.
DOI: 10.7759/cureus.72778.
Madkhali M
Medicine (Baltimore). 2024; 103(3):e36936.
PMID: 38241567
PMC: 10798712.
DOI: 10.1097/MD.0000000000036936.
Javed A, Alvi M, Sahra S, Dechavez V
IDCases. 2022; 27:e01439.
PMID: 35145868
PMC: 8819125.
DOI: 10.1016/j.idcr.2022.e01439.
Sun S, Urbanus R, Ten Cate H, de Groot P, de Laat B, Heemskerk J
Cells. 2021; 10(12).
PMID: 34943895
PMC: 8699996.
DOI: 10.3390/cells10123386.
von Lukowicz H, Schlegel P, Hartel C, Morbach H, Haubitz I, Wiegering V
Mol Cell Pediatr. 2021; 8(1):11.
PMID: 34486084
PMC: 8419130.
DOI: 10.1186/s40348-021-00121-z.
Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach.
Lozano M, Segu-Verges C, Coma M, Alvarez-Roman M, Gonzalez-Porras J, Gutierrez L
Int J Mol Sci. 2021; 22(13).
PMID: 34199099
PMC: 8269123.
DOI: 10.3390/ijms22136907.
Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia.
Rodeghiero F, Woszczyk D, Slama B, Melikyan A, Viallard J, Ouaja R
J Hematol. 2020; 7(3):87-95.
PMID: 32300420
PMC: 7155829.
DOI: 10.14740/jh385w.
Human platelet antigens and primary immune thrombocytopenia.
Castro V
Rev Bras Hematol Hemoter. 2017; 39(2):95-97.
PMID: 28577662
PMC: 5457466.
DOI: 10.1016/j.bjhh.2017.02.008.
Advances in Diagnosis and Treatments for Immune Thrombocytopenia.
Nomura S
Clin Med Insights Blood Disord. 2016; 9:15-22.
PMID: 27441004
PMC: 4948655.
DOI: 10.4137/CMBD.S39643.
Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom?.
Vaughn J, Anwer F, Deeg H
Vox Sang. 2015; 110(1):5-11.
PMID: 26178735
PMC: 4780370.
DOI: 10.1111/vox.12314.
Changes in follicular helper T cells in idiopathic thrombocytopenic purpura patients.
Xie J, Cui D, Liu Y, Jin J, Tong H, Wang L
Int J Biol Sci. 2015; 11(2):220-9.
PMID: 25561904
PMC: 4279097.
DOI: 10.7150/ijbs.10178.
In vitro evaluation of clot quality and stability in a model of severe thrombocytopenia: effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor.
Shenkman B, Einav Y, Livnat T, Budnik I, Martinowitz U
Blood Transfus. 2013; 12(1):78-84.
PMID: 24333083
PMC: 3926734.
DOI: 10.2450/2013.0068-13.
Pathophysiology and management of primary immune thrombocytopenia.
Kashiwagi H, Tomiyama Y
Int J Hematol. 2013; 98(1):24-33.
PMID: 23702914
DOI: 10.1007/s12185-013-1370-4.
Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag.
Tarantino M, Bakshi K, Brainsky A
Platelets. 2013; 25(1):55-61.
PMID: 23402314
PMC: 3913069.
DOI: 10.3109/09537104.2013.764980.
Pulsed high-dose dexamethasone improves interleukin 10 secretion by CD5+ B cells in patients with primary immune thrombocytopenia.
Hua F, Ji L, Zhan Y, Li F, Zou S, Wang X
J Clin Immunol. 2012; 32(6):1233-42.
PMID: 22669326
DOI: 10.1007/s10875-012-9714-z.